Citadel Advisors’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $125K | Sell |
74,100
-63,800
| -46% | -$131K | ﹤0.01% | 11838 |
|
|
2025
Q4 | $273K | Buy |
137,900
+51,500
| +60% | +$165K | ﹤0.01% | 10352 |
|
|
2025
Q3 | $251K | Buy |
86,400
+57,600
| +200% | +$132K | ﹤0.01% | 10745 |
|
|
2025
Q2 | $52.1K | Sell |
28,800
-79,700
| -73% | -$142K | ﹤0.01% | 11748 |
|
|
2025
Q1 | $163K | Sell |
108,500
-210,300
| -66% | -$531K | ﹤0.01% | 10741 |
|
|
2024
Q4 | $752K | Sell |
318,800
-174,400
| -35% | -$3.06M | ﹤0.01% | 7636 |
|
|
2024
Q3 | $14.5M | Buy |
493,200
+393,600
| +395% | +$9.06M | ﹤0.01% | 2419 |
|
|
2024
Q2 | $1.23M | Buy |
99,600
+34,900
| +54% | +$736K | ﹤0.01% | 6195 |
|
|
2024
Q1 | $1.31M | Sell |
64,700
-88,400
| -58% | -$2.04M | ﹤0.01% | 6376 |
|
|
2023
Q4 | $3.45M | Sell |
153,100
-90,600
| -37% | -$1.91M | ﹤0.01% | 4412 |
|
|
2023
Q3 | $4.06M | Sell |
243,700
-88,400
| -27% | -$1.75M | ﹤0.01% | 3990 |
|
|
2023
Q2 | $8.14M | Sell |
332,100
-203,300
| -38% | -$4.9M | ﹤0.01% | 2946 |
|
|
2023
Q1 | $12.9M | Buy |
535,400
+48,700
| +10% | +$1.35M | ﹤0.01% | 2464 |
|
|
2022
Q4 | $14.4M | Sell |
486,700
-79,300
| -14% | -$2.85M | ﹤0.01% | 2349 |
|
|
2022
Q3 | $23.7M | Sell |
566,000
-79,300
| -12% | -$2.14M | 0.01% | 1715 |
|
|
2022
Q2 | $18.1M | Sell |
645,300
-107,500
| -14% | -$2.71M | ﹤0.01% | 1942 |
|
|
2022
Q1 | $28M | Buy |
752,800
+222,100
| +42% | +$9.41M | 0.01% | 1621 |
|
|
2021
Q4 | $23.2M | Sell |
530,700
-86,300
| -14% | -$4.53M | ﹤0.01% | 1857 |
|
|
2021
Q3 | $38.3M | Buy |
617,000
+276,900
| +81% | +$23.1M | 0.01% | 1334 |
|
|
2021
Q2 | $29.1M | Buy |
340,100
+99,800
| +42% | +$5.35M | 0.01% | 1648 |
|
|
2021
Q1 | $10.8M | Buy |
240,300
+174,300
| +264% | +$6.86M | ﹤0.01% | 2858 |
|
|
2020
Q4 | $450K | Buy |
66,000
+8,300
| +14% | +$74.1K | ﹤0.01% | 8343 |
|
|
2020
Q3 | $664K | Sell |
57,700
-43,400
| -43% | -$196K | ﹤0.01% | 6786 |
|
|
2020
Q2 | $311K | Buy |
+101,100
| New | +$459K | ﹤0.01% | 7853 |
|
|
2015
Q4 | – | Sell |
-414
| Closed | -$5K | – | 9127 |
|
|
2015
Q3 | $5K | Buy |
414
+114
| +38% | +$1.44K | ﹤0.01% | 8635 |
|
|
2015
Q2 | $4K | Buy |
+300
| New | +$4.11K | ﹤0.01% | 8567 |
|
|
2014
Q3 | – | Sell |
-171
| Closed | -$7K | – | 8361 |
|
|
2014
Q2 | $7K | Buy |
171
+42
| +33% | +$1.55K | ﹤0.01% | 7671 |
|
|
2014
Q1 | $5K | Sell |
129
-71
| -36% | -$2.51K | ﹤0.01% | 7649 |
|
|
2013
Q4 | $7K | Sell |
200
-429
| -68% | -$11.4K | ﹤0.01% | 6780 |
|
|
2013
Q3 | $12K | Buy |
629
+343
| +120% | +$6K | ﹤0.01% | 6424 |
|
|
2013
Q2 | $4K | Buy |
+286
| New | +$6.04K | ﹤0.01% | 6358 |
|
Other funds holding FLNA
VCM
GC
Citadel Advisors's FLNA Position: Q4 2025 in Review
Citadel Advisors sold out of Filana Therapeutics (FLNA) in Q4 2025, closing a stake of 13,864 shares — an estimated $44.4K sold.
Citadel Advisors first reported a position in FLNA in Q2 2013 and held it in 26 quarters. The position peaked at $26.6M in Q2 2021. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.
- Citadel Advisors reported no remaining Filana Therapeutics position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 13,864 Filana Therapeutics shares in Q4 2025, an estimated $44.4K.
- Citadel Advisors first reported a position in Filana Therapeutics in Q2 2013 and held it in 26 quarters.
- Citadel Advisors's Filana Therapeutics position peaked at $26.6M in Q2 2021.
- 107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.